Allegis Investment Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

Allegis Investment Advisors’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-28	Closed	-$1K	–	938
2015 Q4	$1K	Buy	+28	New	+$1.41K	﹤0.01%	1095

Other funds holding GENE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Allegis Investment Advisors's GENE Position: Q1 2016 in Review

Allegis Investment Advisors sold out of Genetic Technologies Ltd. (GENE) in Q1 2016, closing a stake of 28 shares — an estimated $1K sold.

Allegis Investment Advisors first reported a position in GENE in Q4 2015 and held it in 1 quarter. The position peaked at $1K in Q4 2015. 10 funds tracked by Wall St. Rank hold GENE as of Q1 2016.

Allegis Investment Advisors reported no remaining Genetic Technologies Ltd. position as of Q1 2016 after selling out during the quarter.
Allegis Investment Advisors sold 28 Genetic Technologies Ltd. shares in Q1 2016, an estimated $1K.
Allegis Investment Advisors first reported a position in Genetic Technologies Ltd. in Q4 2015 and held it in 1 quarter.
Allegis Investment Advisors's Genetic Technologies Ltd. position peaked at $1K in Q4 2015.
10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2016.

Based on Allegis Investment Advisors's 13F filing for Q1 2016, filed 9 May 2016.